
|Articles|October 1, 2003
No Quick-Fix Solution
New York - While the micronized formulation of Alloderm (Cymetra, LifeCell Corp.) is an appropriate substance for correcting certain facial defects, the physician who wants to use it may need to manage patient expectations, according to Anthony P. Sclafani, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















